SUBRETINAL FLUID ASSOCIATED WITH PEMIGATINIB THERAPY FOR CHOLANGIOCARCINOMA: A CASE REPORT AND LITERATURE REVIEW

Area of Science:

• Ophthalmology
• Oncology
• Pharmacology

Background:

• Cholangiocarcinoma treatment has advanced with targeted therapies.
• Fibroblast growth factor receptor (FGFR) inhibitors, like pemigatinib, are used in cancer therapy.
• Ocular side effects of FGFR inhibitors require careful monitoring.

Purpose of the Study:

• To document the specific retinal changes observed in a patient treated with pemigatinib.
• To contribute to the limited literature on pemigatinib-induced ocular toxicity.
• To characterize the nature of subretinal fluid associated with FGFR inhibition.

Main Methods:

• A detailed case report of a patient experiencing visual symptoms during pemigatinib treatment.
• A comprehensive literature search for previously reported cases of pemigatinib-related subretinal fluid.
• Ophthalmic examination including optical coherence tomography (OCT) for imaging retinal structures.

Main Results:

• A 72-year-old female patient on pemigatinib for cholangiocarcinoma developed bilateral subfoveal subretinal fluid.
• The subretinal fluid showed fluctuation, resolving with a drug holiday but recurring with treatment.
• No other significant ocular complications were noted during the 10-month treatment period.

Conclusions:

• This case adds to the scarce reports of pemigatinib-associated retinopathy.
• The findings suggest that pemigatinib-induced subretinal fluid is typically self-limited.
• Subretinal fluid in patients on FGFR inhibitors appears to be a benign and transient condition.